19054-Breast Cancer-NA-108

Breast Cancer

STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)

  • Details

ClinicalTrials.gov ID: NCT03975647
Diagnosis Type: NA
USOR Number:

  • Address

7777 Forest Lane, Suite D400
Dallas, TX 75230
P: (972) 566-6647

Search by practice name, trial titles, indicators and specific disease types.

Find a Location

With more than 2,500 physicians and over 600 treatment locations across the country, the advanced cancer care you need may be available right in your local community from a practice in The US Oncology Network. Search to see if there is a center near you.